Literature DB >> 21865077

A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit.

Umut Dişel, Ali Ayberk Beşen, Özgür Özyılkan, Efsun Er, Tuba Canpolat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21865077     DOI： 10.1016/j.oraloncology.2011.07.030

Source DB:  PubMed          Journal:  Oral Oncol        ISSN： 1368-8375            Impact factor:   5.337


× No keyword cloud information.
  13 in total

Review 1.  Osteochemonecrosis: an overview.

Authors:  John Hellstein
Journal:  Head Neck Pathol       Date:  2014-11-20

2.  Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris).

Authors:  J G Messer; E J Castillo; A M Abraham; J M Jiron; R Israel; J F Yarrow; S Thomas; M C Reynolds; R D Wnek; M Jorgensen; N Wanionok; C Van Poznak; I Bhattacharyya; D B Kimmel; J I Aguirre
Journal:  Bone       Date:  2019-11-07       Impact factor: 4.398

3.  Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.

Authors:  Jason Fangusaro; Sridharan Gururangan; Regina I Jakacki; Sue C Kaste; Stewart Goldman; Ian F Pollack; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

4.  A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians.

Authors:  Sung Ok Hong; Chae-Yoon Lee; Junho Jung; Deog-Yoon Kim; Christian Walter; Yong-Dae Kwon
Journal:  Clin Oral Investig       Date:  2016-10-22       Impact factor: 3.573

5.  Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.

Authors:  Sridharan Gururangan; Jason Fangusaro; Tina Young Poussaint; Arzu Onar-Thomas; Richard J Gilbertson; Sridhar Vajapeyam; Amar Gajjar; Stewart Goldman; Henry S Friedman; Roger J Packer; James M Boyett; Larry E Kun; Roger McLendon
Journal:  Neuro Oncol       Date:  2012-09-26       Impact factor: 12.300

6.  Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.

Authors:  Giordana Bettini; Stella Blandamura; Giorgia Saia; Alberto Bedogni
Journal:  BMJ Case Rep       Date:  2012-10-22

7.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

8.  Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab.

Authors:  Daria Pakosch; Dimitrios Papadimas; Johanna Munding; Darafsch Kawa; Marcus Stephan Kriwalsky
Journal:  Oral Maxillofac Surg       Date:  2012-12-16

9.  Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).

Authors:  Jason Fangusaro; Sridharan Gururangan; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Katherine E Warren; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Larry E Kun; Maryam Fouladi
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

10.  Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.

Authors:  Vivek Thumbigere-Math; Bryan S Michalowicz; Pamela J Hughes; David L Basi; Michaela L Tsai; Karen K Swenson; Laura Rockwell; Rajaram Gopalakrishnan
Journal:  J Oral Maxillofac Surg       Date:  2015-10-03       Impact factor: 1.895
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.